Colonic Carcinosarcoma: Report of a Rare Colorectal Malignancy and Review of Literature

Melissa Kyriakos Saad a Fatme Ghandour b Fatmeh Ghandour El Hajj b
Imad El Hajj a Elias Saikaly a

a General Surgery Department, Saint George Hospital University Medical Center, University of Balamand, Beirut, Lebanon; b Pathology Department, Saint George Hospital University Medical Center, University of Balamand, Beirut, Lebanon

Keywords
Colorectal cancer · Colorectal carcinosarcoma

Abstract
Colonic carcinosarcoma is an extremely rare tumor composed of mixed malignant epithelial and mesenchymal cells. Due to its rarity, its pathogenesis is poorly understood, and there are no specific guidelines for its treatment.

Introduction
Carcinosarcoma, a biphasic tumor, exhibits epithelial and stromal malignant differentiation. The epithelial component is composed of high-grade or mid-grade adenocarcinoma and the sarcomatous part is of mesenchymal origin which may be differentiated or undifferentiated [1]. Carcinosarcomas can occur in different organs and different anatomical locations; following the first report by Virchow [2] in 1864, its occurrence has been described in various organs. However, a predominance is seen in the female genital tract [3, 4], in the head and neck [5], and some isolated reports affecting the gastrointestinal tract, mainly esophagus [6] and stomach [7]. Having said this, colorectal carcinosarcoma is an extremely rare tumor. To the best of our knowledge, 31 cases have been reported as either sarcomatoid carcinoma or carcinosarcoma in the medical literature. Herein, we present a case of cecal carcinosarcoma treated surgically by right hemicolectomy.

Case Report
A 67-year-old male patient known to have hypertension with no previous abdominal surgeries transferred to our institute for surgical management of large bowel obstruction at the cecum diagnosed by CT scan of the abdomen and pelvis with IV contrast done at another institution showing a 15 × 15 cm mass at the level of the cecum with heterogeneous density, with proximal small bowel dilatation, no liver lesions were noted. History goes back to the day of presentation where the patient reported acute onset of abdominal pain in the periumbilical area, non-radiating associated with increase in abdominal girth and inability to pass gas for the last 24 h. Patient reports associated nausea and 2 episodes of biliary vomiting. Patient denies weight loss, blood per rectum, change in bowel habits, and family history of colorectal cancer. Patient also reported that no previous colonoscopy was done. On physical exam, the patient was in pain, with stable blood pressure of 135/80 mm Hg and tachycardia of 110 beats per minute. Abdominal exam revealed a distended abdomen, hypoactive bowel sounds, and mild...
tenderness on deep palpation. Laboratory workup reveals leukocytosis of 17,000 WBC with 80% neutrophils, elevated inflammatory markers and normal Cr, electrolytes, and amylase. Tumor markers, including CEA and CA 19-9 were normal. Given the above, the patient was diagnosed with mechanical large bowel obstruction and an emergency surgery done. The patient was taken to the operating theater where he was placed in supine position, general anesthesia was given and urinary Foley catheter inserted. Midline laparotomy was done, and abdominal exploration showed no liver deposits and there was no carcinomatosis. A large obstructive mass was observed in the cecum measuring around 10 cm in diameter and 25 cm in length, with 20 cm of the terminal ileum adherent to the colonic mass. Furthermore, a tumorous deposit was noted at the mesentry of the right colon. Consequently, an oncologic right hemi-colectomy was done, with side-to-side ileocolic anastomosis. Postoperative course was smooth with no complications, and the patient was discharged home on day 6 post-surgery. Histopathology examination of the specimen revealed the following.

**Macroscopic Description**

Huge tumor 12 cm in diameter and 25 cm in length occupying the ileocecal area with 18 cm of terminal ileum adherent to the tumor, covered by whitish fibrous adhesions. Opening the specimen revealed a polypoid multilobulated mass occluding the lumen, invading the full thickness of colonic wall reaching the serosal surface. The tumor showed solid white section and glistening mucoid areas and necrosis. A similar-in-appearance 3-cm nodule was identified at the mesocolon.

**Microscopic Description**

Biphasic tumor which in some areas comprised cohesive sheets of polygonal cells having pleomorphic nucleolated nuclei and abundant cytoplasm focally clear and focally dense eosinophilic featuring central keratinization, while in other areas, it showed abundant myxoid stroma with scattered single- and multinucleated cells having markedly pleomorphic nuclei admixed with fascicles of spindle cells having similarly anaplastic nuclei and fibrillary eosinophilic cytoplasm. Brisk mitotic activity was

---

**Fig. 1.** Tumor with intact overlying bowel mucosa.

**Fig. 2.** Central and right evident squamous differentiation, with surrounding spindle mesenchymal elements.

**Fig. 3.** Higher power magnification showing adjacent squamous and mesenchymal differentiation.
noted throughout. Rare mucin vacuole or glandular lumens were identified among the epithelial elements. Tumor infiltrates the full thickness of the colonic wall till reaching the serosal surface. Lymphatic embolization and absence of vascular invasion was noted. Fibrous adhesions to the terminal ileum with no invasion were observed. One lymph node was positive for malignancy out of 18 (1/18) (Fig. 1–3).

IHC was done and showed prominent delineation between the cell components expressed. Vimentin was positive in mesenchymal, spindle cells (Fig. 4) and cytokeratin in the squamous component (Fig. 5).

**Final Diagnosis**

Carcinosarcoma of the cecum with adenosquamous epithelial element and myxoid chondroid and leiomyosarcomatous stromal element with negative margins and 1/18 lymph node positive for malignancy. The patient refused postoperative chemotherapy and was followed up to 1 month after surgery and then lost to follow-up.

**Discussion**

Colorectal carcinosarcoma is an extremely rare entity. The first reported case dates back to 1986 by Weidner and Zekan [8], and since then, 31 cases have been reported till date (Table 1) [9, 12–15, 18, 19, 21–25, 30–32, 35–37]. Reviewing the characteristics of the reported cases in the medical literature (Table 2) revealed that the mean age of presentation is 64 years with a range between 13 and 86 years, a male to female ratio of 13:18 with 42% of reported cases being male and 58% females. Fresh blood per rectum was the most common presenting symptom. The rectum is the most common site of involvement with 9 out of 31 (29%) cases involving the rectum; this is followed by the same number of reported cases involving the ascending colon, descending colon, and the sigmoid colon. The least common site reported to be involved is the transverse colon with only 1 case reported in the medical literature. Only 2 cases have been reported to involve the cecum, and our case is the third cecal involvement to be reported worldwide. Furthermore, what makes our case special is the relatively large size of the tumor when compared to other reported cases.

There’s no universal agreement on its nomenclature. Historically, carcinosarcoma has also been known as sarcomatoid carcinoma, carcinoma with mesenchymal stroma, carcinoma with sarcomatous change, spindle cell carcinoma, and pleomorphic anaplastic carcinoma; but the term “carcinosarcoma” is officially used in World Health Organization classification [16].

The histogenesis of carcinosarcoma is poorly understood, and multiple hypotheses have been proposed in an attempt to determine its pathogenesis and its biphasic nature. Regarding gastrointestinal carcinosarcomas, the metaplastic theory is favored, whereby it is believed that the carcinoma component precedes and that it is differ-
| No. | Author                  | Age/sex | Primary presentation | Site/size, cm            | Treatment                                                                 | Distant metastasis | LN metastasis | Adjuvant treatment                                                                 | Survival post-surgery |
|-----|-------------------------|---------|----------------------|--------------------------|---------------------------------------------------------------------------|--------------------|---------------|----------------------------------------------------------------------------------|----------------------|
| 1   | Weidner and Zekan [8]   | 73/M    | Large bowel obstruction | Sigmoid/? LHC + colostomy (reversal 4 months post-operatively) | Metachronous (8 cm mesenteric mass at aortic bifurcation + 7 cm pelvic mass/liver) | Negative | 3 sessions: 5-FU/mitomycin C, 2 sessions: cyclophosphamide/doxorubicin/cisplatinum | 48 months (DOD)      |
| 2   | Staroz et al. [9]       | 64/M    | ?                    | Descending/? LHC         | Metachronous                                                              | Positive | None          | None                                                                            | 4 months (DOD)       |
| 3   | Roncaroli et al. [10]   | 71/F    | ?                    | Rectum/? LAR             | Metachronous                                                              | Positive | None          | None                                                                            | 6 months (DOD)       |
| 4   | Isimbaldi et al. [11]   | 86/F    | Melena/right lower quadrant pain/constipation | Ascending/? RHC | None                                                                       | Negative | None          | None                                                                            | Alive at 24-month follow-up |
| 5   | Gentile and Castellaneta [12] | 40/F    | ?                    | Cecum/? RHC              | Synchronous (liver)                                                       | –                   | None          | None                                                                            | 2 months (DOD)       |
| 6   | Bertram et al. [13]     | 79/F    | Bloody diarrhea/ weight loss/ endoscopically obstructed | Ascending/? RHC | Synchronous (liver)                                                       | Positive | 4 sessions: leucovorin/5-FU                                                     | 5 months (DOD)       |
| 7   | Serio and Aguzzi [14]   | 69/F    | Blood per rectum     | Descending/ 5.5 LHC      | None                                                                       | Negative | None          | None                                                                            | Alive at 6-month follow-up |
| 8   | Shoji et al. [15]       | 78/M    | Bloody diarrhea/ continuous abdominal pain | Descending/ 5×2×3 LHC   | None                                                                       | Negative | Chemotherapy: mitomycin C                                                     | Alive at 16-month follow-up |
| 9   | Nakao et al. [16]       | 68/F    | Investigations of occult blood | Transverse/ 3 × 4.2 × 0.8 RHC | None                                                                       | Positive | Chemotherapy: 5-FU/cisplatin                                                | Alive up to 14-month follow-up |
| 10  | Takeyoshi et al. [17]   | 82/M    | Blood per rectum/ palpable rectal mass 2 cm from AV | Rectum/? LAR Metachronous (skin) | Positive                                                                  | None          | None          | None                                                                            | 6 months (DOD)       |
| 11  | Shah et al. [18]        | 57/F    | Left upper quadrant pain/ fever | Rectoigmoid/? LAR | Synchronous (peritoneum/liver/pelvic), metachronous (lungs/liver/pelvis) | Positive | None          | None                                                                            | 5 months (DOD)       |

Table 1. Colorectal carcinosarcoma reported in literature
| No. | Author               | Age/sex | Primary presentation | Site/size, cm | Treatment                                      | Distant metastasis                                                                 | LN metastasis | Adjuvant treatment                        | Survival post-surgery                                      |
|-----|----------------------|---------|----------------------|---------------|------------------------------------------------|----------------------------------------------------------------------------------|--------------|-------------------------------------------|-----------------------------------------------------------|
| 12  | Di Vizio et al. [19] | 56/F    | Septic fever         | Descending/20 | LHC + splenectomy/ omentectomy                   | Metachronous (peritoneal carcinomatosis) then liver metastasis                   | Positive     |                                            | 5 months: relapse (surgery LHC/TAHBSO/ Cholecystectomy + HIPEC), 12 months: relapse (liver metastasis at portal confluence and total gastrectomy with wide resection of small bowel), 21 months (DOD) |
| 13  | Kim et al. [20]      | 41/F    | Melena/change in bowel habits | Sigmoid/5×3.3 | LAR                                              | Metachronous (liver, lung, and brain)                                           | Positive     | Chemotherapy: 5-FU/ leucovorin              | 4 months DOD                                              |
| 14  | Armendi et al. [21]  | 84/M    | Fever/acute abdominal pain | Descending (splenic flexure)/0×6×8 | LHC                                              | None                                                                              | Negative     | None                                       | Died 4 days postoperatively                                |
| 15  | Ishida et al. [22]   | 80/F    | Lower abdominal pain  | Rectosigmoid/18 | Hartmann’s procedure + RHC                      | Metachronous (intrapelvic metastasis)                                           | Positive     | None                                       | 6 months (DOD)                                            |
| 16  | Macaigne et al. [23] | 67/F    | Rectorrhagia/anemia  | Rectum/8      | LHC + partial cystectomy + TAHBSO               | Metachronous (liver/pelvic involving the right ureter)                          | None         | Adriamycin                                 | 2 months (DOD)                                            |
| 17  | Ekinci et al. [24]   | 39/F    | Large bowel obstruction | Rectosigmoid/6×5 | LAR                                              | None                                                                              | Positive     | 3 sessions of chemotherapy/ radiotherapy | Alive at 4-month follow-up                                |
| 18  | Kim et al. [25]      | 71/M    | Abdominal pain       | Ascending/10  | Exploratory laparotomy (unresectable tumor)     | Synchronous (bloody abdominal wall, omental cake, extensive carcinomatosis)     | NA           | ?                                         | Palliative care/lost to follow-up                         |
| 19  | Ambrosini-Spaltro et al. [26] | 81/M | Asthenia/weight loss | Ascending/7 | RHC                                              | Synchronous (liver)                                                             | Positive     | Chemotherapy: capecitabine                 | Alive at 24-month at follow-up                            |
| 20  | Tsekouras et al. [27] | 60/M    | Constipation/hypogastric discomfort | Rectum/7  | APR                                              | Metachronous (liver/ lungs/peritoneal implants)                                  | Positive     | 4 cycles of 5-FU/ leucovorin chemotherapy | 6 months (DOD)                                            |
| 21  | Öztürk et al. [28]   | 65/F    | Blood per rectum     | Rectum/2×1.5  | APR                                              | None                                                                              | Negative     | None                                       | Alive at 60-month follow-up                               |
| 22  | Lee et al. [1]       | 52/F    | Prolapsed rectal mass/rectal bleeding | Rectum/5.5×1.3×6.2 | APR                                              | None                                                                              | Negative     | None                                       | Alive at 8-month follow-up                                |
| 23  | Jeong et al. [29]    | 13/F    | Lower abdominal pain | Rectosigmoid/13×8.6 | ULAR                                             | Metachronous (pelvic LN)s                                                        | Positive     | Chemotherapy                              | Alive at 2-month follow-up                                |
| No. | Author | Age/sex | Primary presentation | Site/size, cm | Treatment | Distant metastasis | LN metastasis | Adjuvant treatment | Survival post-surgery |
|-----|--------|---------|----------------------|---------------|-----------|-------------------|--------------|-------------------|----------------------|
| 24  | Patel et al. [30] | 43/F | Unintentional weight loss/blood per rectum/tenesmus | Sigmoid/? | Hartmann’s + en bloc partial cystectomy (colovesical fistula) | Synchronous (pelvic LN, liver) | Chemotherapy (gemcitabine/taxotere) | Alive at 2-month follow-up |
| 25  | Shim et al. [31] | 65/M | Surgical abdomen | Ascending/11×9 | RHC | Metachronous (malignant ascites: peritoneal carcinomatosis) | Positive | – | 1 month (DOD) |
| 26  | Mori et al. [32] | 65/M | Abdominal fullness | Sigmoid/15 | LAR with en bloc partial cystectomy | Synchronous (peritoneal carcinomatosis)/metachronous (lung) | Negative | Chemotherapy: capecitabine, 8 cycles FOLFIRI + bevacizumab | 10 months (DOD) |
| 27  | Ryu et al. [33] | 72/F | Hematochezia/anemia | Cecum/3 | RHC | None | Negative | None | Alive at 20-month follow-up |
| 28  | Kolodziej-ak et al. [34] | 83/M | Lower GI bleed | Rectum/30×53×40 | Loop colostomy (non-resectable locally advanced tumor) | None | – | None | 1 month (DOD) |
| 29  | Peris Tomas et al. [35] | 59/? | Abdominal pain/weight loss/palpable mass in left iliac fossa | Sigmoid/10×7 | Hartmann’s procedure (R2 resection) | Synchronous (liver) | – | None | 3 months postoperative progression of liver metastasis, 18×8 cm heterogeneous pelvic mass with infiltration of bladder, 6 months (DOD) |
| 30  | Sudlow et al. [36] | 80/F | Bleeding per rectum/weight loss | Low rectum/? | APR | Metachronous (lungs) | Negative | None | 16 months postoperative locoregional recurrence + distant metastasis, 25 months (DOD) |
| 31  | Osholowu et al. [37] | 68/M | Lower abdominal pain/diarrhea/weight loss | Rectum/? | None (locally advanced) | Synchronous (lungs/omentum) | Positive | Palliative chemotherapy | NA |
| 32  | Our case | 67/M | Large bowel obstruction | Cecum/12×25 | RHC | Synchronous (mesentery) | Positive | Chemotherapy refused by the patient | Lost to follow-up |

RHC, right hemi-colectomy; LHC, left hemi-colectomy; LAR, low anterior resection; ULAR, ultra-low anterior resection; APR, abdominoperineal resection; DOD, died of disease; NA, not applicable.
entiated into the sarcomatoid component in accordance with the development of cancer clones [38]. Furthermore, it has been also proposed that the phenotype of the carcinoma is converted to a sarcoma due to a viral infection or a mutation of the p53 gene [10, 11]. The most commonly observed pattern of staining is reactivity in the adenocarcinomatous component to the epithelial markers, CK20 and CEA [29, 33]. The sarcomatous cells frequently stain positively for vimentin, desmin, and SMA [1, 8, 33].

Patients with colonic carcinosarcoma have similar clinical presentation to that of colonic adenocarcinoma. The spectrum of symptoms ranges from rectal bleeding [1, 17, 34], weight loss [26], abdominal pain [29], and reaching obstructive symptoms [27]. From a surgical point of view, colorectal carcinosarcomas are treated similar to general colorectal cancer; however, given the poor prognosis reported in the medical literature, a more aggressive treatment and closer follow-up is recommended when compared to general colorectal cancer. On the other hand, as colorectal carcinosarcoma is an extremely rare entity, prognostic factors and the optimal adjuvant chemotherapy regimen are yet to be determined. Furthermore, suggested prognostic indicators include size, stage, lymphatic or vascular invasion, and histology of the carcinomatous component [29]. On the other hand, adjuvant therapies, chemotherapy (5-fluorouracil, leucovorin, doxorubicin, and cisplatin), and radiation therapy have been attempted, but their effectiveness has not been proven yet [16, 20, 28].

The malignant behavior of colorectal carcinosarcoma is very similar to that of adenocarcinoma with the carcinomatous component showing a strong tendency to metastasize to lymph nodes and distant sites, whereas the sarcoma plays only a very minor role in metastatic spread [33]. Having said this, early diagnosis and appropriate oncologic surgery is the cornerstone of successful outcome.

**Conclusion**

Colorectal carcinosarcoma is a biphasic tumor, exhibiting epithelial and stromal malignant differentiation. Immunohistochemistry is the gold standard for diagnosis. Due to its rarity, no specific treatment guidelines exist, and its treatment depends solely on the previously described case reports, which suggest treating colorectal carcinosarcoma in a similar fashion to colorectal adenocarcinoma. Further studies and collection of cases are needed to establish proper therapeutic guidelines.

**Acknowledgement**

The authors acknowledge the general surgery department at Saint George Hospital University Medical Center.

**Statement of Ethics**

Written informed consent was obtained from the patient to publish the case as well as all the images.

**Conflict of Interest Statement**

No conflict of interest by all authors.

**Funding Sources**

No funding was received for this article.
Author Contributions

Melissa Kyriakos Saad wrote the article and did the review of literature. Elias Saikaly wrote the article and did the review of literature. Fatme Ghandour wrote the pathology section and prepared the slides. Fatme Ghandour El Hajj reviewed the article and did the pathology section and prepared the slides. Imad El Hajj reviewed the article.

References

1. Lee JK, Ghosh P, McWhorter V, Payneau M, Olsonau R, Krinskayu ML, et al. Evidence for colorectal sarcomatoid carcinoma arising from tubulovillous adenoma. World J Gastroenterol. 2008;14(27):4389–94.
2. Virchow R. Die krankhaften Geschwulste. Berlin: Hirschwald; 1864. p. 170–384.
3. Baiocchi G, Kanavag J, Wharton JT. Endometrioid stromal sarcomas arising from ovarian and extravarian endometriosis. Report of two cases and literature review. Gynecol Oncol. 1990;36:147–51.
4. Norris HJ, Taylor HB. Mesenchymal tumors of the uterus: III. A clinical and pathologic study of 31 sarcomas. Cancer. 1966;19:1459–65.
5. Berthelet E, Shenouda G, Black MJ, Picariello E, Lonergan R, Krinskyau ML, et al. Evidence for sarcomatoid carcinomas arising from tubulovillous adenoma: a report of a rare tumor. Pathol Res Pract. 1996;192(5):483–7.
6. Madan AK, Long AE, Weldon CB, Jaffe BM. Esophageal carcinosarcoma. J Gastrointest Surg. 2001;5(4):414–7.
7. Tsuneyama K, Sasaki M, Sabit A, Yokoi K, Harareau T, Hayashidaau Y, et al. Carcinosarcoma of the colon: report of a case with review of the literature. Tumori. 2001;87(6):431–5.
8. Takeyoshi I, Yoshida M, Ohwada S, Yamada T, Yagaiwa A, Morishita Y. Skin metastasis from the stellate cell component in rectal carcinosarcoma. Hepatogastroenterology. 2000;47(36):1611–4.
9. Shah S, Kim DH, Harster G, Hossain A. Carcinosarcoma of the colon and spleen: a fleshy purple mass on colonoscopy. Dig Dis Sci. 2001;46(1):106–8.
10. Virozido D, Insabato L, Conzo G, Zafonte BT, Ferrara G, Pettinato G. Sarcomatoid carcinoma of the colon: a case report with review of the literature. Tumori. 2001;87(6):431–5.
11. Kim JH, Moon WS, Kang MJ, Park MJ, Lee BJ, Jung W. Carcinosarcoma in the cecum. Gut Liver. 2012;6(3):395–8.
12. Kołodziejczak M, Bielecki K, Sudoł-Szopińska I, Szczesniakau A, Obcowskaau A. Very rare case of rectal carcinosarcoma. Tech Coloproctol. 2013;17(5):615–7.
13. Peris Tomas N, Lozano AG, Garcia RM, Ortega GA, Abad MM. Carcinosarcoma de colon: a proposito de un caso. Cir Esp. 2013;91(5):615–7.
14. Serio G, Aguzzi A. Spindle and giant cell carcinoma of the colon. Histopathology. 1997;30(4):383–5.
15. Shoji M, Dobashi Y, Iwabuchi K, Kuroda S, Mikami T, Kameya T. Sarcomatoid carcinoma of the descending colon: a histological, immunohistochemical and ultrastructural analysis. Acta Oncol. 1998;37(7–8):765–8.
16. Nakao A, Sakakami K, Uda M, Mitsuoka S, Ito H. Carcinosarcoma of the colon: report of a case and review of the literature. J Gastroenterol. 1998;33(2):276–9.
17. Takeyoshi I, Yoshida M, Ohwada S, Yamada T, Yanagisawa A, Morishita Y. Skin metastasis from the stellate cell component in rectal carcinosarcoma. Hepatogastroenterology. 2000;47(36):1611–4.
18. Shah S, Kim DH, Harster G, Hossain A. Carcinosarcoma of the colon and spleen: a fleshy purple mass on colonoscopy. Dig Dis Sci. 2001;46(1):106–8.
19. Díez Vízco D, Insabato L, Conzo G, Zhafonte BT, Ferrara G, Pettinato G. Sarcomatoid carcinoma of the colon: a case report with review of the literature. Tumori. 2001;87(6):431–5.
20. Kim JH, Moon WS, Kang MJ, Park MJ, Lee DJG. Carcinosarcoma of the colon: a case report. Pathol Res Pract. 2003;199(2):93–8.
21. Weidner N, Zekan P. Carcinosarcoma of the colon, one or two tumors? Pathologica. 2003;140(9):1409. Am J Gastroenterol. 2017;112:236–9.
22. Yoshida M, Ohwada S, Yamada T, Yagaiwa A, Morishita Y. Skin metastasis from the stellate cell component in rectal carcinosarcoma. Hepatogastroenterology. 2000;47(36):1611–4.
23. Yamauchi T, Kameya T, Yamada T, Yanagisawa A, Morishita Y. Skin metastasis from the stellate cell component in rectal carcinosarcoma. Hepatogastroenterology. 2000;47(36):1611–4.
24. Eusebi V. Sarcomatoid carcinoma of the ano-rectal junction with neuroendocrine and neuroendocrinal differentiation. Pathol Res Pract. 1999;195(2):93–8.
25. Virchow R. Die krankhaften Geschwulste. Berlin: Hirschwald; 1864. p. 170–384.
26. Aramendi T, Fernández-Aceñero MJ, Villanueva MC. Carcinosarcoma of the colon: report of a rare tumor. Pathol Res Pract. 2003;199(5):345–8.
27. Ambrosini-Spaltro A, Vaira V, Braidotti P, Antica V. A rare case of sarcomatoid tumor of the colon: a case report with review of the literature. Case Rep Surg. 2015;2015:412918–4.
28. Tsokoukuras DK, Katsaragakis S, Theodorou D, Kafiri G, Archontovasilis F, Giannopoulos P, et al. Rectal carcinosarcoma: a case report and review of literature. World J Gastroenterol. 2006;12(9):1481–4.
29. Öztürk E, Yilmazlar T, Yerci O. A rare tumor located in the anorectal junction: sarcomatoid carcinoma. Turk J Gastroenterol. 2006;17:236–9.
30. Pathel DH, Dang S, Bentley FR, Julia RN, Olden KE, Audri F. Carcinosarcoma of the colon: a rare cause of colovesical fistula. Am Surg. 2009;75(4):445–50.
31. Shim HJ, Hong YK, Kim SJS, Choi YJ, Kang YG. Carcinosarcoma on ascending colon found by bowel perforation: a case report. J Korean Soc Coloproctol. 2010;26(5):368–72.
32. Mori Y, Katsumata K, Suzuki S, Matsudaau D, Haraua T, Hayashidaau Y, et al. Carcinosarcoma of the sigmoid colon: report of a case. Case Rep Gastroenterol. 2010;4(3):484–91.
33. Ryu Y, Kim A, Kim H, Lee BJ, Jung W. Carcinosarcoma in the cecum. Gut Liver. 2012;6(3):395–8.
34. Nishiya K, Sasaki M, Sabit A, Yokoi K, Harareau T, Hayashidaau Y, et al. Carcinosarcoma of the sigmoid colon: report of a case. Case Rep Gastroenterol. 2010;4(3):484–91.
35. Sugawara H, Sonoueau H, Hattori K, Sonoueau H, Hattori K, et al. Loss of heterozygosity analysis shows monoclonal evolution with frequent genetic progression and divergence in esophageal carcinosarcoma. Hum Pathol. 2004;35(3):322–7.